Skip to main content
Caplight Logo









GeneMind Biosciences Co., Ltd.

GeneMind Biosciences Co., Ltd.

Private
ShenzhenHealthcare & Life Scienceshttps://genemind.com

Last Round

Series D

Sep 14, 2026

Est. Valuation

$573.5M

Total Funding Raised

$307M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

GeneMind Biosciences Co., Ltd. operates in Healthcare & Life Sciences and is based in Shenzhen. Its latest recorded funding round was a Series D round in September 2026.

GeneMind Biosciences Co., Ltd. is a biotechnology company that develops and manufactures DNA sequencing systems and molecular diagnostic technology platforms for clinical and research applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Biotech Equipment, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

GeneMind Biosciences Co., Ltd. Comparables

Compare GeneMind Biosciences Co., Ltd. with similar companies based on industry and business-model similarity.

GeneMind Biosciences Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Salus BioMed
83%
MGI
81%
Cygnus Biosciences (Beijing) Co., Ltd.
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

GeneMind Biosciences Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 14, 2026
Series C ExtensionMay 28, 2025
Series CAug 2, 2023
Series B ExtensionSep 15, 2021
StrategicJun 21, 2021
Series B
Sep 1, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Lei Sun

CTO

Executive Team

Zhiliang Zhou

Chief Operating Officer, VP R&D

Executive Team

For institutional investors. Book with your work email.

GeneMind Biosciences Co., Ltd. Investors

Notable investors and investment history

GeneMind Biosciences Co., Ltd. investors
InvestorRounds
Sincere CapitalSeries B
Guosheng Hongyuan (Shanghai) Investment Co., Ltd.Series D
Shanghai International GroupSeries D
Delian CapitalSeries D
Hunan Provincial Caixin Industrial Fund ManagementSeries D
Shenzhen HTI GroupSeries D, Series C
Cowin CapitalSeries B Extension
Book a demo to see all 8 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 14, 2026

    $89M round led by Shenzhen Capital Group and Shanghai International Group.

  • Aug 21, 2026

    Monthly visitors increased 35% MoM, reaching 4K.

Book a demo to see all signals

For institutional investors. Book with your work email.

GeneMind Biosciences Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

GeneMind Biosciences Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about GeneMind Biosciences Co., Ltd.'s valuation, stock price, and market status.

Is GeneMind Biosciences Co., Ltd. a public or private company?

GeneMind Biosciences Co., Ltd. is a private company.

What is the current stock price of GeneMind Biosciences Co., Ltd.?

GeneMind Biosciences Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks GeneMind Biosciences Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is GeneMind Biosciences Co., Ltd. worth (valuation)?

GeneMind Biosciences Co., Ltd.'s valuation is estimated at $573.5M based on funding round data.

Can I buy GeneMind Biosciences Co., Ltd. stock?

GeneMind Biosciences Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was GeneMind Biosciences Co., Ltd.'s last funding round?

GeneMind Biosciences Co., Ltd.'s most recent funding round was Series D on September 14, 2026.

Who are the main investors in GeneMind Biosciences Co., Ltd.?

Key investors in GeneMind Biosciences Co., Ltd. include Shanghai International Group, Cowin Capital, Shenzhen Capital Group.

Will GeneMind Biosciences Co., Ltd. IPO soon?

No public IPO plans have been announced for GeneMind Biosciences Co., Ltd..

How can I track GeneMind Biosciences Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades in GeneMind Biosciences Co., Ltd.'s shares on secondary markets.

Firmographic Details

HeadquartersShenzhen
Employee Range76
Year Founded2012
Last FundingSep 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?